Quantcast
Last updated on April 19, 2014 at 21:20 EDT

Latest linezolid Stories

2011-12-21 08:00:00

Embrace Health, Inc. announces the launch of its new Recovery Program for MRSA / Staph infections on 30 November 2011. Port Townsend, WA (PRWEB) December 21, 2011 Embrace Health, Inc. (a leader in Staph Infection and MRSA Treatment education online since 2008) announced a new educational program [launched worldwide on November 30, 2011] called the Recovery Program exclusively for sufferers of Staph Infections. This Staph Infection resource is a comprehensive collection of educational works...

2011-11-03 07:00:00

ANAHEIM, Calif., Nov. 3, 2011 /PRNewswire/ -- Cempra Pharmaceuticals will be presenting data demonstrating Taksta's activity against Methicillin-resistant Staphylococcus aureus (MRSA) strains isolated from cystic fibrosis (CF) patients and demonstrating solithromycin's anti-inflammatory activity in a human lung epithelial in vitro model at the 25th Annual North American Cystic Fibrosis Conference in Anaheim, California. Both studies will be presented during poster abstract sessions at...

2011-09-08 20:04:51

An analysis of the genome of a superbug has yielded crucial, novel information that could aid efforts to counteract the bacterium´s resistance to an antibiotic of last resort. The results of the research led by scientists from The University of Texas Health Science Center at Houston (UTHealth) are published in the Sept. 8 issue of the New England Journal of Medicine. Superbugs are bacteria that are resistant to multiple antibiotics and represent one of the most challenging health...

2011-06-01 07:00:00

CHAPEL HILL, N.C., June 1, 2011 /PRNewswire/ -- Cempra Pharmaceuticals, a developer of differentiated antibiotics, announced the publication of a Clinical Infectious Disease supplement (Vol. 52, Supplement 7) that profiles fusidic acid and specifically TAKSTA(TM) (CEM-102), administered using a proprietary loading dose regimen, for use in treating acute bacterial skin and skin structure infections (ABSSSI) in the U.S. Articles contributed by experts in infectious disease discuss a range of...

2011-05-16 21:56:56

The antibiotic linezolid may be more effective than vancomycin in treating ventilated patients who develop methicillin-resistant Staphylococcus aureus (MRSA) pneumonia as a result of their ventilation, according to a study conducted globally by American and French researchers. The study will be presented at the ATS 2011 International Conference in Denver. "At the end of the treatment period in this study, linezolid offered statistically significant higher rates of clinical and microbiologic...

2011-05-11 20:26:00

SEOUL, Korea, May 11, 2011 /PRNewswire/ -- CrystalGenomics, Inc., a biopharmaceutical company with 3 clinical stage candidates, has announced today that the draft Clinical Study Report (CSR) from CG400549's Phase I Multiple Ascending Dose (MAD) Study has just been received. CG400549 is a potential first-in-class antibiotic candidate targeting the fatty acid biosynthesis enzyme FabI, a critical enzyme in generating bacterial membrane and has a novel chemical structure which has never been...

2011-04-28 07:00:00

CHAPEL HILL, N.C., April 28, 2011 /PRNewswire/ -- Researchers from the Hershey Medical Center today announced the publication of research demonstrating that the antibiotic, fusidic acid, is active against MRSA strains isolated from cystic fibrosis (CF) patients. In addition, fusidic acid did not antagonize the activity of two antibiotics, tobramycin and amikacin, that are commonly used in CF patients to treat P. aeruginosa and B. cepacia infections. These results indicate the important...

2011-01-13 00:00:41

As the first step in PolyMedix's US clinical development activities with PMX-30063, it has initiated a Phase 1 clinical trial. (Vocus/PRWEB) January 12, 2011 Last November, PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, received regulatory clearance from the FDA to investigate its new antibiotic candidate, PMX-30063. PMX-30063 was inspired by a key discovery: It is possible to...

2010-12-09 12:08:00

BURLINGTON, Mass., Dec. 9, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the generic erosion of nine branded agents will significantly constrain growth in the hospital-acquired infections (HAI) drug market through 2019 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. These nine agents -- piperacillin/tazobactam (Pfizer's Zosyn/Tazocin, generics),...

2010-12-02 09:00:00

MALVERN, Pa., Dec. 2, 2010 /PRNewswire/ -- Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds surveyed internal medicine physicians cite that the most important factors influencing hospital selection of antibiotics used for inpatient community-acquired pneumonia (CAP) are recommendations from medical society guidelines (e.g. American Thoracic Society guidelines on pneumonia) and recommendations from...


Latest linezolid Reference Libraries

0_4d46cc72a490344d44ba78359f528175
2011-04-26 21:07:20

Enterococcus is a Gram-positive, commensal bacterium inhabiting the gastrointestinal tracts of humans and other mammals. It is a main constituent of some probiotic food supplements. E. faecalis can cause life-threatening infections in humans, especially in the nosocomial environment, where the naturally high levels of antibiotic resistance found in E. faecalis contribute to its pathogenicity. It is frequently found in root canal-treated teeth in prevalence values ranging from 30% to 90% of...

0_71ad70ea6f0948a7e84406e760c7f5a4
2011-04-15 14:36:05

Enterococcus faecalis "“ formerly classified as part of the Group D Streptococcus system "“ is a Gram-positive, commensal bacterium inhabiting the gastrointestinal tracts of humans and other mammals. It is one of the main constituents of some probiotic food supplements. E. faecalis can cause life-threatening infections in humans. It is frequently found in root canal-treated teeth in prevalence values ranging from 30% to 90% of the cases. It is a non-motile, facultatively anaerobic...

More Articles (2 articles) »